Universal test and treat in Cameroon: a comparative retrospective analysis of mortality and loss to follow-up before and after a strategic change in approach to HIV care.

IF 5.7 2区 医学 Q1 ONCOLOGY International Journal of Cancer Pub Date : 2023-08-31 eCollection Date: 2023-01-01 DOI:10.11604/pamj.2023.45.191.40448
Cavin Epie Bekolo, Sylvester Atanga Ndeso, Linda Lucienne Moifo, Nkwele Mangala, Tatiana Danielle Yimdjo, Jerome Ateudjieu, Charles Kouanfack, Alain Djam, Earnest Njih Tabah, Solange Whegang, Clarisse Mapa-Tassou, Nicolas Tendongfor, Dickson Shey Nsagha, Siméon-Pierre Choukem
{"title":"Universal test and treat in Cameroon: a comparative retrospective analysis of mortality and loss to follow-up before and after a strategic change in approach to HIV care.","authors":"Cavin Epie Bekolo, Sylvester Atanga Ndeso, Linda Lucienne Moifo, Nkwele Mangala, Tatiana Danielle Yimdjo, Jerome Ateudjieu, Charles Kouanfack, Alain Djam, Earnest Njih Tabah, Solange Whegang, Clarisse Mapa-Tassou, Nicolas Tendongfor, Dickson Shey Nsagha, Siméon-Pierre Choukem","doi":"10.11604/pamj.2023.45.191.40448","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>an increasing number of persons living with HIV (PLHIV) are accessing antiretroviral therapy (ART) since the adoption of the universal test and treat (UTT) policy by Cameroon in 2016. We sought to evaluate the effectiveness of the UTT approach to keep this growing number of PLHIV on a lifelong treatment.</p><p><strong>Methods: </strong>a retrospective cohort analysis was conducted at the Nkongsamba Regional Hospital between 2002 and 2020, using routine data to compare the cumulative incidence of loss to follow-up (LTFU) and mortality between PLHIV initiated on ART under UTT guidelines and those initiated under the standard deferred approach. Chi-squared test was used to compare the risk of attrition between the guideline periods while multiple logistic regression modelling was used to adjust for confounders.</p><p><strong>Results: </strong>of 1627 PLHIV included for analysis, 756 (46.47%) were enrolled during the era of UTT with 545 (33.54%) initiated on ART on the same day of HIV diagnosis. The transition to the UTT era was associated with an overall reduction in the risk of LTFU by 73% (aOR = 0.27, 95%CI: 0.17 - 0.45). There was modest evidence that the odds of mortality had increased under the UTT policy by about 3-fold (aOR = 2.86, 95%CI: 0.91-8.94). Same-day initiation had no overall effect on LTFU or mortality. LTFU was lower among the same-day initiators in the first 24 months but increased thereafter above the rate among late initiators.</p><p><strong>Conclusion: </strong>overall ART programme implementation under the UTT has led to a significant decline in LTFU though mortality appeared to have increased. Ongoing efforts to keep patients on long-term treatment should be sustained while other innovative schemes are sought.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":"98 1","pages":"191"},"PeriodicalIF":5.7000,"publicationDate":"2023-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656581/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11604/pamj.2023.45.191.40448","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: an increasing number of persons living with HIV (PLHIV) are accessing antiretroviral therapy (ART) since the adoption of the universal test and treat (UTT) policy by Cameroon in 2016. We sought to evaluate the effectiveness of the UTT approach to keep this growing number of PLHIV on a lifelong treatment.

Methods: a retrospective cohort analysis was conducted at the Nkongsamba Regional Hospital between 2002 and 2020, using routine data to compare the cumulative incidence of loss to follow-up (LTFU) and mortality between PLHIV initiated on ART under UTT guidelines and those initiated under the standard deferred approach. Chi-squared test was used to compare the risk of attrition between the guideline periods while multiple logistic regression modelling was used to adjust for confounders.

Results: of 1627 PLHIV included for analysis, 756 (46.47%) were enrolled during the era of UTT with 545 (33.54%) initiated on ART on the same day of HIV diagnosis. The transition to the UTT era was associated with an overall reduction in the risk of LTFU by 73% (aOR = 0.27, 95%CI: 0.17 - 0.45). There was modest evidence that the odds of mortality had increased under the UTT policy by about 3-fold (aOR = 2.86, 95%CI: 0.91-8.94). Same-day initiation had no overall effect on LTFU or mortality. LTFU was lower among the same-day initiators in the first 24 months but increased thereafter above the rate among late initiators.

Conclusion: overall ART programme implementation under the UTT has led to a significant decline in LTFU though mortality appeared to have increased. Ongoing efforts to keep patients on long-term treatment should be sustained while other innovative schemes are sought.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
喀麦隆的普遍检测和治疗:对艾滋病毒护理方法战略性改变前后死亡率和随访损失的比较回顾性分析。
导言:自喀麦隆2016年通过普遍检测和治疗政策以来,越来越多的艾滋病毒感染者正在获得抗逆转录病毒治疗。我们试图评估UTT方法的有效性,以保持越来越多的PLHIV终生治疗。方法:2002年至2020年在Nkongsamba地区医院进行回顾性队列分析,使用常规数据比较在UTT指导下开始抗逆转录病毒治疗的艾滋病毒感染者与在标准延迟方法下开始抗逆转录病毒治疗的艾滋病毒感染者之间的累积随访损失发生率(LTFU)和死亡率。采用卡方检验比较指导期之间的磨耗风险,采用多元逻辑回归模型调整混杂因素。结果:纳入分析的1627例PLHIV患者中,756例(46.47%)在UTT时代入组,545例(33.54%)在HIV诊断当日开始ART治疗。过渡到UTT时代与LTFU风险总体降低73%相关(aOR = 0.27, 95%CI: 0.17 - 0.45)。有适度的证据表明,在UTT政策下,死亡率增加了约3倍(aOR = 2.86, 95%CI: 0.91-8.94)。当天开始治疗对LTFU或死亡率没有总体影响。在前24个月,当天启动者的LTFU较低,但此后增加的比率高于晚启动者。结论:尽管死亡率似乎有所增加,但根据UTT实施的总体抗逆转录病毒治疗方案已导致LTFU显著下降。在寻求其他创新方案的同时,应继续努力使患者长期接受治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
13.40
自引率
3.10%
发文量
460
审稿时长
2 months
期刊介绍: The International Journal of Cancer (IJC) is the official journal of the Union for International Cancer Control—UICC; it appears twice a month. IJC invites submission of manuscripts under a broad scope of topics relevant to experimental and clinical cancer research and publishes original Research Articles and Short Reports under the following categories: -Cancer Epidemiology- Cancer Genetics and Epigenetics- Infectious Causes of Cancer- Innovative Tools and Methods- Molecular Cancer Biology- Tumor Immunology and Microenvironment- Tumor Markers and Signatures- Cancer Therapy and Prevention
期刊最新文献
Benefit of adjuvant chemotherapy on recurrence free survival per consensus molecular subtype in stage III colon cancer. Combined inhibition of RAD51 and CHK1 causes synergistic toxicity in cisplatin resistant cancer cells by triggering replication fork collapse. Issue Information Environmental tobacco smoking (ETS) and esophageal cancer: A population-based case-control study in Jiangsu Province, China. HPV vaccination is highly effective and cost-effective for cervical cancer prevention in women living with HIV in China: A cost-effectiveness analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1